Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02920294
Other study ID # METC 163023
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2016
Est. completion date November 11, 2017

Study information

Verified date July 2018
Source Maastricht University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the small intestinal microbiota response in humans to dietary interventions for two consecutive weeks, and to relate this to parameters of intestinal barrier function and immune and metabolic responses in blood, as functional outcome parameters of host physiology


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date November 11, 2017
Est. primary completion date November 11, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

- • Ileostomy installed at least 3 years prior to participation

- Free of any complications originating from the colectomy procedure for at least 1 yr prior to participation, with the exception of possible skin irritation at the location of the stoma

- BMI from 18 till 28 kg/m2

- Age from 18 till 70 years

- Available for entire study protocol.

- For female: If of child bearing potential, female subjects must be using or complying with methods of contraception (such as oral birth control pills, intra-uterine device, double barrier methods (like condoms and spermicide, etc.)

Exclusion Criteria:

- • History of cardiovascular, respiratory, urogenital, hepatic, haematological / immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological diseases, allergy, laboratory assessments which might limit participation in or completion of the study protocol, and/or major surgery with the exception of total colectomy, hysterectomy and/or appendectomy.

- Subject with known lactose intolerance or with known or suspected allergy or hypersensitivity to any component of the study product(s) (milk protein for example) + sucrose + rhamnose

- Severe gastrointestinal symptoms. In case of mild gastrointestinal symptoms, the principal investigator and the medically responsible MD will judge eligibility to participate.

- Removal of more than 15 cm of the ileum during or at any moment after the colectomy procedure

- Abdominal surgery interfering with gastrointestinal function, upon judgment of the principal investigator and the medically responsible MD

- Use of medication, including proton pump inhibitors, non-steroidal anti-inflammatory drugs interfering with endpoints (but except oral contraceptives), within 14 days prior to and during participation.

- Consumption of any probiotic or prebiotic supplements or pre- and probiotics containing food products, investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principal investigator), in the 4 weeks prior to the study and during study participation (E4 PreProbiotics).

- Use of antibiotics in the 4 weeks prior to the start of study and during study participation

- Prohibited use of pro-, pre- or synbiotics during study period and three months prior to start of study. A list with forbidden products will be provided`

- History of any side effects towards intake of pro- or prebiotic supplements of any kind.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Probiotic 1
Fresh fermented dairy drink containing yoghurt ferments
Probiotic 2
Fresh fermented dairy drink containing probiotic strain
Placebo
Acidified dairy drink without ferments

Locations

Country Name City State
Netherlands Maastricht University Medical Centre Maastricht Limburg

Sponsors (1)

Lead Sponsor Collaborator
Maastricht University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Temporal microbial composition and activity in the small intestine in ileal effluent The microbiome activity will be determined as a function of the diet by double strand cDNA production and random sequencing of mRNA enriched fractions of total effluent RNA obtained from the effluent samples at the start and end of each intervention period. 2 weeks intervention
Secondary Small intestinal permeability by a multi sugar test (urinary recovery of test sugars) 2 weeks intervention
Secondary Gene transcription response in blood by transcriptome patterns. Transcriptome patterns will be determined in peripheral blood mononuclear cells obtained from blood samples from the participating ileostoma patients 2 weeks intervention
Secondary The levels of a panel of peripheral blood biomarkers related to immune, metabolic and hormonal status A panel of biomarkers will be determined in peripheral blood obtained at the start and end of the intervention periods 2 weeks intervention
Secondary The level of whole blood immune responsiveness to a panel of standardized stimuli ex vivo Peripheral whole blood immune responsiveness towards a subset of bacterial immune-stimuli will be assessed using the standardized truculture system 2 weeks intervention
Secondary Morning urine metabolome profiles The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples. 2 weeks intervention
Secondary Peripheral blood metabolome profiles The principal analytical methodology employed is mass-spectrometry profiling and can commonly provide reliable quantifications of more than 400 named-metabolites in different body-fluid samples. 2 weeks intervention
Secondary The relative survival of bacterial strains (colony forming unit enumeration on semi-selective culture plates) 2 weeks intervention
Secondary Short chain fatty acid profiles in ileal effluent 2 weeks intervention
Secondary Number of participants with Gastrointestinal symptoms by Visual Analogue Scales 2 weeks intervention
Secondary Occurrence and severity of treatment related adverse events 2 weeks intervention
See also
  Status Clinical Trial Phase
Terminated NCT03746353 - Early Closure Versus Conventional Closure in Postoperative Patients With Low Anteriresection for Rectal Cancer N/A
Completed NCT03331783 - Assessment of the Effect of Output on New Adhesives N/A
Completed NCT02886455 - Evaluation of the Influence of Output on Skin Covered by Newly Developed Adhesives N/A
Completed NCT02517541 - A Clinical Investigation Evaluating and Understanding Parameters Affecting the Performance of Ostomy Products N/A
Completed NCT01939600 - Digestibility of Selected Resistant Starches in Humans N/A
Completed NCT01957553 - Investigating the Safety and Performance of a New 2-piece Ostomy Product Compared With SenSura Click 2-piece N/A
Completed NCT01994876 - Investigation of Newly Developed 1-piece Convex Baseplates in Subjects With Ileostomy N/A
Terminated NCT01994863 - Safety and Performance Investigation of a New 1-piece Ostomy Product Compared to Standard of Care 1-piece in Subjects With Ileostomy Phase 2
Completed NCT03289013 - Assessement of the Peal Force Needed to Peel New Adhesives From the Skin N/A
Terminated NCT03416023 - Safety, Performance and Durability of the TIES® Implant in Patients Requiring a Permanent Ileostomy N/A
Completed NCT02997267 - Early Closure of Protective Ileostomy in Rectal Cancer Patients N/A
Recruiting NCT01880918 - A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing N/A
Completed NCT01957397 - Investigation of Three Newly Developed 2-piece Convex Base-plates in Subjects With Ileostomy N/A
Recruiting NCT04577456 - Chyme Reinfusion for Type 2 Intestinal Failure N/A
Terminated NCT03587519 - Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery N/A
Recruiting NCT03872271 - Is Diverting Loop Ileostomy Necessary in Completion Proctectomy With Ileal Pouch Anal- Anastomosis: A Multicentre, Randomized Study of the GETAID Chirurgie Group. IDEAL Trial N/A
Completed NCT04606004 - Perianal Maceration in Pediatric Ostomy Closure Patients N/A
Completed NCT02886403 - Evaluation of the Influence of Output on a Newly Develop Adhesive N/A
Recruiting NCT03424447 - Stimulation of the Efferent Loop Before Loop Ileostomy Closure Phase 2
Completed NCT03770078 - Assessment of New Enhanced Ostomy Device in Real-life Settings in Subjects Having a Stoma N/A